With its improved pharmacokinetic properties, including increased bioavailability, half-life, and lower clearance as compared to first generation irreversible Pan-ErbB inhibitors such as CI-1033, dacomitinib is an attractive agent for potential clinical use in HNSCC [21]. Here, EGFR is linked to head and neck squamous cell carcinoma.